Kymera Therapeutics (KYMR) Competitors

$78.14 -1.53 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$78.16 +0.02 (+0.02%)

As of 05:30 PM Eastern

KYMR vs. INSM, BNTX, MRNA, ROIV, and VTRS

Should you buy Kymera Therapeutics stock or one of its competitors? MarketBeat compares Kymera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kymera Therapeutics include Insmed (INSM), BioNTech (BNTX), Moderna (MRNA), Roivant Sciences (ROIV), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Kymera Therapeutics compare to Insmed?

Kymera Therapeutics (NASDAQ:KYMR) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Insmed had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 14 mentions for Insmed and 5 mentions for Kymera Therapeutics. Insmed's average media sentiment score of 0.74 beat Kymera Therapeutics' score of 0.39 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Kymera Therapeutics has higher earnings, but lower revenue than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	163.93	-$311.35M	-$3.57	N/A
Insmed	$819.56M	28.41	-$1.28B	-$5.75	N/A

Insmed has a net margin of -144.44% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Insmed	-144.44%	-130.11%	-51.57%

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 51.13%. Insmed has a consensus target price of $210.95, indicating a potential upside of 96.40%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Insmed beats Kymera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Kymera Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

BioNTech has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

In the previous week, BioNTech had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for BioNTech and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.39 beat BioNTech's score of -0.10 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech presently has a consensus price target of $130.60, indicating a potential upside of 48.76%. Kymera Therapeutics has a consensus price target of $118.10, indicating a potential upside of 51.13%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioNTech has a net margin of -44.39% compared to Kymera Therapeutics' net margin of -611.94%. BioNTech's return on equity of -5.30% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kymera Therapeutics has lower revenue, but higher earnings than BioNTech. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A
Kymera Therapeutics	$39.21M	163.93	-$311.35M	-$3.57	N/A

Summary

BioNTech and Kymera Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Moderna?

Kymera Therapeutics (NASDAQ:KYMR) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 51.13%. Moderna has a consensus target price of $35.73, indicating a potential downside of 21.84%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

75.3% of Moderna shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Moderna has a net margin of -143.55% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Moderna	-143.55%	-26.64%	-19.32%

Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Kymera Therapeutics has higher earnings, but lower revenue than Moderna. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	163.93	-$311.35M	-$3.57	N/A
Moderna	$1.94B	9.33	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Moderna and 5 mentions for Kymera Therapeutics. Moderna's average media sentiment score of 0.42 beat Kymera Therapeutics' score of 0.39 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Kymera Therapeutics beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Kymera Therapeutics has a net margin of -611.94% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A
Kymera Therapeutics	$39.21M	163.93	-$311.35M	-$3.57	N/A

In the previous week, Kymera Therapeutics had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 5 mentions for Kymera Therapeutics and 3 mentions for Roivant Sciences. Kymera Therapeutics' average media sentiment score of 0.39 beat Roivant Sciences' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Roivant Sciences presently has a consensus target price of $30.55, indicating a potential upside of 8.29%. Kymera Therapeutics has a consensus target price of $118.10, indicating a potential upside of 51.13%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Kymera Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Viatris?

Kymera Therapeutics (NASDAQ:KYMR) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Viatris has a net margin of -2.04% compared to Kymera Therapeutics' net margin of -611.94%. Viatris' return on equity of 19.04% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Viatris	-2.04%	19.04%	7.62%

Kymera Therapeutics currently has a consensus price target of $118.10, indicating a potential upside of 51.13%. Viatris has a consensus price target of $16.43, indicating a potential upside of 1.60%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kymera Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Kymera Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	163.93	-$311.35M	-$3.57	N/A
Viatris	$14.30B	1.32	-$3.51B	-$0.26	N/A

79.9% of Viatris shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

In the previous week, Viatris had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for Viatris and 5 mentions for Kymera Therapeutics. Viatris' average media sentiment score of 0.58 beat Kymera Therapeutics' score of 0.39 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Viatris on 9 of the 17 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.43B	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-21.89	18.70	20.58	25.11
Price / Sales	163.93	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	4.02	6.57	9.68	6.60
Net Income	-$311.35M	$24.30M	$3.55B	$335.71M
7 Day Performance	-6.48%	-3.56%	-2.07%	-2.03%
1 Month Performance	-10.91%	-7.86%	-3.90%	-1.90%
1 Year Performance	158.74%	51.80%	29.39%	27.36%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	2.235 of 5 stars	$78.14 -1.9%	$118.10 +51.1%	+163.4%	$6.43B	$39.21M	N/A	170
INSM Insmed	3.3911 of 5 stars	$110.47 +6.3%	$211.86 +91.8%	+57.3%	$23.79B	$606.42M	N/A	1,664
BNTX BioNTech	3.9049 of 5 stars	$93.67 +0.4%	$131.60 +40.5%	-4.2%	$23.72B	$3.25B	N/A	7,807
MRNA Moderna	1.4909 of 5 stars	$53.11 +0.4%	$35.73 -32.7%	+93.5%	$21.19B	$1.94B	N/A	4,700	Insider Trade Gap Up
ROIV Roivant Sciences	1.8899 of 5 stars	$29.59 +2.2%	$30.55 +3.2%	+164.6%	$21.14B	$29.05M	N/A	860

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. INSM, BNTX, MRNA, ROIV, and VTRS

How does Kymera Therapeutics compare to Insmed?

Summary

How does Kymera Therapeutics compare to BioNTech?

Summary

How does Kymera Therapeutics compare to Moderna?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Summary

How does Kymera Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. INSM, BNTX, MRNA, ROIV, and VTRS

How does Kymera Therapeutics compare to Insmed?

Does the media refer more to KYMR or INSM?

Which has more risk and volatility, KYMR or INSM?

Which has stronger valuation & earnings, KYMR or INSM?

Is KYMR or INSM more profitable?

Do analysts rate KYMR or INSM?

Summary

How does Kymera Therapeutics compare to BioNTech?

Which has more risk & volatility, BNTX or KYMR?

Does the media prefer BNTX or KYMR?

Do analysts prefer BNTX or KYMR?

Do institutionals & insiders have more ownership in BNTX or KYMR?

Is BNTX or KYMR more profitable?

Which has higher earnings & valuation, BNTX or KYMR?

Summary

How does Kymera Therapeutics compare to Moderna?

Do analysts rate KYMR or MRNA?

Do institutionals and insiders have more ownership in KYMR or MRNA?

Is KYMR or MRNA more profitable?

Which has more risk & volatility, KYMR or MRNA?

Which has higher valuation and earnings, KYMR or MRNA?

Does the media refer more to KYMR or MRNA?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Is ROIV or KYMR more profitable?

Which has more volatility and risk, ROIV or KYMR?

Which has stronger earnings and valuation, ROIV or KYMR?

Does the media refer more to ROIV or KYMR?

Do insiders & institutionals have more ownership in ROIV or KYMR?

Do analysts recommend ROIV or KYMR?

Summary

How does Kymera Therapeutics compare to Viatris?

Is KYMR or VTRS more profitable?

Do analysts rate KYMR or VTRS?

Which has stronger valuation & earnings, KYMR or VTRS?

Do insiders & institutionals believe in KYMR or VTRS?

Which has more risk & volatility, KYMR or VTRS?

Does the media favor KYMR or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools